Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
Overview
Authors
Affiliations
Pancreatic ductal adenocarcinomas (PDAs) are characterized by a robust fibroinflammatory response. We show here that this desmoplastic reaction generates inordinately high interstitial fluid pressures (IFPs), exceeding those previously measured or theorized for solid tumors, and induces vascular collapse, while presenting substantial barriers to perfusion, diffusion, and convection of small molecule therapeutics. We identify hyaluronan, or hyaluronic acid (HA), as the primary matrix determinant of these barriers and show that systemic administration of an enzymatic agent can ablate stromal HA from autochthonous murine PDA, normalize IFP, and re-expand the microvasculature. In combination with the standard chemotherapeutic, gemcitabine, the treatment permanently remodels the tumor microenvironment and consistently achieves objective tumor responses, resulting in a near doubling of overall survival.
ECM Stiffness-Induced Redox Signaling Enhances Stearoyl Gemcitabine Efficacy in Pancreatic Cancer.
Zhao S, Agyare E, Zhu X, Trevino J, Rogers S, Velazquez-Villarreal E Cancers (Basel). 2025; 17(5).
PMID: 40075719 PMC: 11899364. DOI: 10.3390/cancers17050870.
Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis.
Chambers C, Watakul S, Schofield P, Howell A, Zhu J, Tran A Sci Adv. 2025; 11(11):eadq4416.
PMID: 40073121 PMC: 11900870. DOI: 10.1126/sciadv.adq4416.
The Oncoprotein Mucin 1 in Pancreatic Cancer Onset and Progression: Potential Clinical Implications.
Dieli R, Lioy R, Crispo F, Cascelli N, Martinelli M, Lerose R Biomolecules. 2025; 15(2).
PMID: 40001578 PMC: 11853026. DOI: 10.3390/biom15020275.
Facilitation of Tumor Stroma-Targeted Therapy: Model Difficulty and Co-Culture Organoid Method.
Feng Q, Shan X, Yau V, Cai Z, Xie S Pharmaceuticals (Basel). 2025; 18(1).
PMID: 39861125 PMC: 11769033. DOI: 10.3390/ph18010062.
Zhu Y, Chen J, Chen C, Tang R, Xu J, Shi S Biomark Res. 2025; 13(1):11.
PMID: 39849659 PMC: 11755887. DOI: 10.1186/s40364-025-00727-9.